Invitrogen, part of Life Technologies Corporation, will present major trends in stem cell technologies this week at the International Society for Stem Cell Research (ISSCR) 7th Annual Meeting in Barcelona, Spain.
The ISSCR meeting is the pre-eminent international stem cell conference, attracting more than 2,500 of the foremost stem cell professionals from public, private, academic and government organizations. Several presentations during the conference will highlight how Invitrogen products are enabling pioneering approaches to culture and expansion of multiple human stem cell types.
Life Technologies, through its Invitrogen portfolio of products, is playing a principal role in induced pluripotent stem cell (iPSC) research, working with collaborators from leading research centres to develop new tools and technologies to advance iPSC discoveries.
A number of products, for use across the iPSC workflow, will be highlighted during the conference, including ViraPower™ HiPerform™ reprogramming technologies, KnockOut™ SR XenoFree and StemPRO® serum-free media and growth factor cocktails, CELLstart™ xeno-free substrates and the Dynabeads® SSEA-4 extraction system.
Mohan Vemuri, Ph.D., Life Technologies’ Director of Stem Cells and Regenerative Medicine and Mahendra Rao, Ph.D., Life Technologies’ Vice President of Stem Cell Research, will present tutorials on the benefits of using Invitrogen’s XenoFree Media for growing human embryonic and induced pluripotent stem cells, mesenchymal stem cells and neural stem cells at the ISSCR meeting in Room 117.
For those not attending the conference, questions on these and other tutorials featuring Invitrogen products will be answered on the Invitrogen website. Questions can be submitted at www.invitrogen.com/stemcell/isscr09, where the panelists’ slides and answers will be available after the meeting.
Mohan Vemuri, Ph.D., Life Technologies’ Director of Stem Cells and Regenerative Medicine, “At Life Technologies, we believe that future use of stem cells for cell replacement therapies and tissue engineering is dependent on reliable, well-defined reagents prepared from animal-free origin. Our Invitrogen products have been an integral part of iPSC research since the initial discovery in 2006, and our latest products offer researchers more regulatory-friendly solutions to advance potentially ground-breaking stem cell therapies towards the clinic.”